Tug Of War In The LVAD Market

With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline.

A battle royale ensued in 2013 in the still-emerging US market for left ventricular assist devices (LVADs) between the only two companies holding FDA approvals, Thoratec Corp. and HeartWare International Inc. The pair is racing to win physician favor and secure commercial sites and unit sales across the US and worldwide, with Thoratec holding on to its market-dominating position at present. (See Also see "Pressure Builds In Ventricular Assist Market" - Medtech Insight, 27 February, 2013.).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Exact Sciences Enters MRD Market With Oncodetect Launch But Faces Competition, Reimbursement Challenges

 
• By 

The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.

Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move

 
• By 

Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.

HRS Released Framework For Afib Center Of Excellence To Improve Outcomes Through Multidisciplinary Care

 
• By 

Medtech Insight sat down with Jared Bunch, chair of AF Center of Excellence Task Force, at HRS 2025 to discuss the newly HRS released framework for Afib Center of Excellence and get his perspective on the role industry could play to help clinicians improve patient outcomes.